AbbVie filed a new FDA application for its JAK‑inhibitor RINVOQ (upadacitinib) to treat severe alopecia areata in adults and adolescents, following the Phase 3 UP‑AA program that demonstrated early and substantial scalp hair regrowth, including complete scalp coverage (SALT = 0) at week 24.
The UP‑AA trial enrolled patients with near‑total scalp hair loss and showed that upadacitinib achieved a SALT score ≤20 at week 24, with 45% of participants reaching SALT = 0—the first JAK inhibitor to meet this endpoint in a Phase 3 program. The study also included an adolescent cohort (12‑18 years), addressing a significant unmet need in that population.
AbbVie’s immunology franchise, which includes RINVOQ and Skyrizi, generated $8.304 billion in revenue in 2025. The new indication could expand RINVOQ’s addressable market to the global alopecia areata segment, projected to reach $32.83 billion by 2032 with a CAGR of 15.3% from 2025 to 2032.
The FDA review is expected to take 6‑10 months for standard review, with priority review possible. AbbVie has also submitted the application to the European Medicines Agency, positioning the drug for a global launch.
Management highlighted the clinical impact: “Alopecia areata is a chronic immune‑mediated disease that can cause total hair loss and significant psychosocial burden. In the UP‑AA program, upadacitinib showed early and substantial scalp hair growth, including complete scalp coverage, which is a significant outcome for those living with this often‑overlooked disease.” (Kori Wallace, AbbVie)
The filing underscores AbbVie’s strategy to strengthen its immunology portfolio, a key growth driver, and signals the company’s intent to capture a growing market for systemic treatments in dermatology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.